Inhibition of Pseudomonas aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies.
D000293:Adolescent; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications; D004338:Drug Combinations; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D004917:Erythromycin; D014295:Trimethoprim; D013420:Sulfamethoxazole; D001205:Ascorbic Acid